Disitamab Vedotin: First Approval

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

(2021) Yingying Xu et al.   Gastric Cancer

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

(2021) Jiayu Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

(2021) Li Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

(2021) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

(2020) Zhi Peng et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.

(2020) Huayan Xu et al.   JOURNAL OF CLINICAL ONCOLOGY